Boston, MA -- (SBWIRE) -- 05/21/2014 -- Metastatic Breast Cancer - Pipeline Review, H1 2014
Global Markets Direct's, 'Metastatic Breast Cancer - Pipeline Review, H1 2014', provides an overview of the Metastatic Breast Cancer's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer
, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer
and special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
View Full Report Details and Table of Contents
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Breast Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
Companies Mentioned in this Report: Bristol-Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Kyowa Hakko Kirin Co., Ltd., Amgen Inc., Adherex Technologies Inc., AstraZeneca PLC, Eli Lilly and Company, Viralytics Ltd., GlaxoSmithKline plc, Seattle Genetics, Inc., Genentech, Inc., Nektar Therapeutics, Bavarian Nordic A/S, MedImmune, LLC, Dainippon Sumitomo Pharma Co., Ltd., Plexxikon Inc., Celltrion, Inc., ZIOPHARM Oncology, Inc., Millennium Pharmaceuticals, Inc., Novartis AG, Samyang Holdings Corporation, Aphios Corporation, Biocon Limited, BioMarin Pharmaceutical Inc., Eisai Co., Ltd., GTx, Inc., Laboratoires Pierre Fabre SA, Nippon Kayaku Co., Ltd., Pfizer Inc., Cell Therapeutics, Inc., Celgene Corporation, Advaxis, Inc., Celldex Therapeutics, Inc., Imugene Limited, Oncolytics Biotech Inc., Corcept Therapeutics Incorporated, Peregrine Pharmaceuticals, Inc., Array BioPharma Inc., Starpharma Holdings Limited, Jiangsu Hengrui Medicine Co., Ltd., Synta Pharmaceuticals Corp., Natco Pharma Limited, Oasmia Pharmaceutical AB, Transgene Biotek Limited, Wilex AG, Insys Therapeutics, Inc., Supratek Pharma Inc., BioNumerik Pharmaceuticals, Inc., MacroGenics, Inc., Amarna Therapeutics B.V., Advenchen Laboratories, LLC, Immutep S.A., Polyphor Ltd., Syndax Pharmaceuticals, Inc., NewLink Genetics Corporation, Pharma Mar, S.A., WntResearch AB, TRACON Pharmaceuticals, Inc., Regulus Therapeutics Inc., Dompe Farmaceutici S.p.A., Merus B.V., Zyngenia, Inc., MetaStat, Inc., Polaris Group, Neopharm Ltd., EirGen Pharma Ltd., Immunovative Therapies, Ltd., Vaxil Bio Therapeutics Ltd., Inbiopro Solutions Pvt. Ltd., Aslan Pharmaceuticals Pte. Ltd., Puma Biotechnology, Inc., Theracrine, Inc., Agonox, Curaxys, S.L., NobelProcera Innovation Centre, Quebec, OBI Pharma, Inc., Curadis GmbH, AlphaMab Co., Ltd, Galileo Research s.r.l., Paras Biopharmaceuticals Finland Oy, Pharmapraxis
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Breast Cancer - Pipeline Review, H1 2014
- Metastatic Colorectal Cancer - Pipeline Review, H1 2014
- Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014
- Metastatic Pancreatic Cancer - Pipeline Review, H1 2014
- Metastatic Breast Cancer Global Clinical Trials Review, H1, 2014
- Metastatic Breast Cancer - Pipeline Review, H1 2013
- Metastatic Prostate Cancer - Pipeline Review, H1 2014
- Metastatic Melanoma - Pipeline Review, H1 2014
- Metastatic Ovarian Cancer - Pipeline Review, H1 2014
- Metastatic Liver Cancer - Pipeline Review, H1 2014